Skip to main content
Erschienen in: Current Rheumatology Reports 1/2013

01.01.2013 | CHRONIC PAIN (LJ CROFFORD, SECTION EDITOR)

Personalized Treatment of Pain

verfasst von: Jacob N. Ablin, Dan Buskila

Erschienen in: Current Rheumatology Reports | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Despite advances made in its understanding and treatment, chronic pain remains an unsolved and all too common problem. One of the main obstacles to successful management of pain is the high variability of many patients regarding both response to treatment and susceptibility to adverse effects, which curtails the utility of therapeutic intervention. Understanding the causes of this variability is an important challenge which may lead to a new era in rational pain management. As described in this review, however, there currently seems to be more than one possible explanation of this variability. Rational personalized pain management must take into consideration both ever-increasing knowledge of pharmacogenetics and pharmacokinetics and a broad, clinically based attitude incorporating co-morbidities, both physical and psychiatric, and concomitant medications. Novel models for testing in-vivo pain processing, for example assessment of conditioned pain modulation (CPM), are also promising approaches to use of rational data for empirical treatment of pain. Last, listening to the patient and understanding the context in which pain has affected his or her life is an important part of maintaining the personal nature of therapeutic interaction with patients suffering from pain.
Literatur
1.
Zurück zum Zitat Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007;36(6):339–56.PubMedCrossRef Yunus MB. Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. Semin Arthritis Rheum. 2007;36(6):339–56.PubMedCrossRef
2.
Zurück zum Zitat Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain. Int Rev Neurobiol. 2011;97:179–206.PubMedCrossRef Sessle BJ. Peripheral and central mechanisms of orofacial inflammatory pain. Int Rev Neurobiol. 2011;97:179–206.PubMedCrossRef
3.
Zurück zum Zitat Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Rheumatol Rep. 2002;4(4):322–8.PubMedCrossRef Verne GN, Price DD. Irritable bowel syndrome as a common precipitant of central sensitization. Curr Rheumatol Rep. 2002;4(4):322–8.PubMedCrossRef
4.•
Zurück zum Zitat Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011;13(6):513–20. A recent review clarifying the overlap between seemingly disconnected aspects of chronic pain.PubMedCrossRef Staud R. Evidence for shared pain mechanisms in osteoarthritis, low back pain, and fibromyalgia. Curr Rheumatol Rep. 2011;13(6):513–20. A recent review clarifying the overlap between seemingly disconnected aspects of chronic pain.PubMedCrossRef
5.
Zurück zum Zitat Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2):211.PubMedCrossRef Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13(2):211.PubMedCrossRef
6.
Zurück zum Zitat Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum. 2009;60(2):321–4.PubMedCrossRef Clauw DJ, Witter J. Pain and rheumatology: thinking outside the joint. Arthritis Rheum. 2009;60(2):321–4.PubMedCrossRef
7.•
Zurück zum Zitat Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012. [Epub ahead of print]. Well conducted recent study demonstrating the efficacy of an SNRI in a traditional “nociceptive” pain condition. Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012. [Epub ahead of print]. Well conducted recent study demonstrating the efficacy of an SNRI in a traditional “nociceptive” pain condition.
8.
Zurück zum Zitat Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine use in chronic low back pain: treatment patterns and costs. PharmacoEconomics. 2012;30(7):595–609.PubMedCrossRef Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW. Duloxetine use in chronic low back pain: treatment patterns and costs. PharmacoEconomics. 2012;30(7):595–609.PubMedCrossRef
10.
Zurück zum Zitat Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433–8.PubMedCrossRef Cochran KA, Cavallari LH, Shapiro NL, Bishop JR. Bleeding incidence with concomitant use of antidepressants and warfarin. Ther Drug Monit. 2011;33(4):433–8.PubMedCrossRef
11.
Zurück zum Zitat Eisinger J. Dysautonomia, fibromyalgia and reflex dystrophy. Arthritis Res Ther. 2007;9(4):105.PubMedCrossRef Eisinger J. Dysautonomia, fibromyalgia and reflex dystrophy. Arthritis Res Ther. 2007;9(4):105.PubMedCrossRef
12.
Zurück zum Zitat Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci. 2006;1069:109–17.PubMedCrossRef Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann N Y Acad Sci. 2006;1069:109–17.PubMedCrossRef
13.
Zurück zum Zitat Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int. 2011;31(11):1403–8.PubMedCrossRef Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int. 2011;31(11):1403–8.PubMedCrossRef
14.
Zurück zum Zitat Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916–22.PubMedCrossRef Giesecke T, Williams DA, Harris RE, Cupps TR, Tian X, Tian TX, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum. 2003;48(10):2916–22.PubMedCrossRef
15.
Zurück zum Zitat Edwards RR, Bingham III CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55(2):325–32.PubMedCrossRef Edwards RR, Bingham III CO, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Rheum. 2006;55(2):325–32.PubMedCrossRef
16.
Zurück zum Zitat Thorn BE, Pence LB, Ward LC, Kilgo G, Clements KL, Cross TH, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8(12):938–49.PubMedCrossRef Thorn BE, Pence LB, Ward LC, Kilgo G, Clements KL, Cross TH, et al. A randomized clinical trial of targeted cognitive behavioral treatment to reduce catastrophizing in chronic headache sufferers. J Pain. 2007;8(12):938–49.PubMedCrossRef
17.
Zurück zum Zitat Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41–7.PubMedCrossRef Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41–7.PubMedCrossRef
18.
Zurück zum Zitat Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304–15.PubMedCrossRef Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev. 2006;32(4):304–15.PubMedCrossRef
19.
Zurück zum Zitat Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du BR, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006;14(1):56–64.PubMedCrossRef Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du BR, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer. 2006;14(1):56–64.PubMedCrossRef
20.•
Zurück zum Zitat Branford R, Droney J, Ross J. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;1399–1404. A comprehensive up-to-date review of the topic of opioid pharmacogenetics and pharmacokinetics. Branford R, Droney J, Ross J. Opioid genetics: the key to personalized pain control? Clin Genet. 2012;1399–1404. A comprehensive up-to-date review of the topic of opioid pharmacogenetics and pharmacokinetics.
21.
Zurück zum Zitat Leandro-Garcia LJ, Leskela S, Montero-Conde C, Landa I, Lopez-Jimenez E, Leton R, et al. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal Biochem. 2009;389(1):74–6.PubMedCrossRef Leandro-Garcia LJ, Leskela S, Montero-Conde C, Landa I, Lopez-Jimenez E, Leton R, et al. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal Biochem. 2009;389(1):74–6.PubMedCrossRef
22.
Zurück zum Zitat Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology–with emphasis on cytochrome p450. Toxicol Sci. 2011;120(1):1–13.PubMedCrossRef Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology–with emphasis on cytochrome p450. Toxicol Sci. 2011;120(1):1–13.PubMedCrossRef
23.
Zurück zum Zitat Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010;11(6):843–64.PubMedCrossRef Stamer UM, Zhang L, Stuber F. Personalized therapy in pain management: where do we stand? Pharmacogenomics. 2010;11(6):843–64.PubMedCrossRef
24.
Zurück zum Zitat Stamer UM, Stuber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia. 2007;62(12):1294–5.PubMedCrossRef Stamer UM, Stuber F. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype. Anaesthesia. 2007;62(12):1294–5.PubMedCrossRef
25.
Zurück zum Zitat Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1–2):231–8.PubMedCrossRef Stamer UM, Lehnen K, Hothker F, Bayerer B, Wolf S, Hoeft A, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105(1–2):231–8.PubMedCrossRef
26.
Zurück zum Zitat Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY, et al. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1 G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol. 2011;28(4):245–50.PubMed Zhang W, Yuan JJ, Kan QC, Zhang LR, Chang YZ, Wang ZY, et al. Influence of CYP3A5*3 polymorphism and interaction between CYP3A5*3 and CYP3A4*1 G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery. Eur J Anaesthesiol. 2011;28(4):245–50.PubMed
27.
Zurück zum Zitat Xu Y, Zhang Y, Zhou F, Zheng Y, Zhu X. Human pregnane X receptor-mediated transcriptional regulation of CYP3A4 by extracts of 7 traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi. 2011;36(11):1524–7.PubMed Xu Y, Zhang Y, Zhou F, Zheng Y, Zhu X. Human pregnane X receptor-mediated transcriptional regulation of CYP3A4 by extracts of 7 traditional Chinese medicines. Zhongguo Zhong Yao Za Zhi. 2011;36(11):1524–7.PubMed
28.
Zurück zum Zitat Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood–brain barrier: implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829–42.PubMedCrossRef Tournier N, Decleves X, Saubamea B, Scherrmann JM, Cisternino S. Opioid transport by ATP-binding cassette transporters at the blood–brain barrier: implications for neuropsychopharmacology. Curr Pharm Des. 2011;17(26):2829–42.PubMedCrossRef
29.
Zurück zum Zitat Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83(4):559–66.PubMedCrossRef Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008;83(4):559–66.PubMedCrossRef
30.
Zurück zum Zitat Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232–9.PubMedCrossRef Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232–9.PubMedCrossRef
31.
Zurück zum Zitat Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324–36.PubMedCrossRef Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324–36.PubMedCrossRef
32.
Zurück zum Zitat Ali ZK, Kim RJ, Ysla FM. CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Devel. 2009;12(1):108–14.PubMed Ali ZK, Kim RJ, Ysla FM. CYP2C9 polymorphisms: considerations in NSAID therapy. Curr Opin Drug Discov Devel. 2009;12(1):108–14.PubMed
33.
Zurück zum Zitat Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296–301.PubMedCrossRef Scordo MG, Spina E, Dahl ML, Gatti G, Perucca E. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97(5):296–301.PubMedCrossRef
34.
Zurück zum Zitat Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59(1):5–12.PubMedCrossRef Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. 2004;59(1):5–12.PubMedCrossRef
35.
Zurück zum Zitat LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas-LLedo EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004;59(12):869–73.PubMedCrossRef LLerena A, Dorado P, Berecz R, Gonzalez AP, Penas-LLedo EM. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur J Clin Pharmacol. 2004;59(12):869–73.PubMedCrossRef
36.
Zurück zum Zitat Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575–80.PubMedCrossRef Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K, et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry. 2004;161(9):1575–80.PubMedCrossRef
37.
Zurück zum Zitat McAlpine DE, Biernacka JM, Mrazek DA, O’Kane DJ, Stevens SR, Langman LJ, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33(1):14–20.PubMedCrossRef McAlpine DE, Biernacka JM, Mrazek DA, O’Kane DJ, Stevens SR, Langman LJ, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33(1):14–20.PubMedCrossRef
38.
Zurück zum Zitat Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–3.PubMedCrossRef Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–3.PubMedCrossRef
39.
Zurück zum Zitat Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D et al. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain 2012 Martinez-Jauand M, Sitges C, Rodriguez V, Picornell A, Ramon M, Buskila D et al. Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain 2012
40.••
Zurück zum Zitat Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153(6):1193–8. A novel study demonstrating the efficacy of CPM measurement in predicting the response to SNRI treatment.PubMedCrossRef Yarnitsky D, Granot M, Nahman-Averbuch H, Khamaisi M, Granovsky Y. Conditioned pain modulation predicts duloxetine efficacy in painful diabetic neuropathy. Pain. 2012;153(6):1193–8. A novel study demonstrating the efficacy of CPM measurement in predicting the response to SNRI treatment.PubMedCrossRef
41.
Zurück zum Zitat Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain. 2009;144(1–2):16–9.PubMedCrossRef Pud D, Granovsky Y, Yarnitsky D. The methodology of experimentally induced diffuse noxious inhibitory control (DNIC)-like effect in humans. Pain. 2009;144(1–2):16–9.PubMedCrossRef
42.
Zurück zum Zitat Lev R, Granovsky Y, Yarnitsky D. Orbitofrontal disinhibition of pain in migraine with aura: an interictal EEG-mapping study. Cephalalgia. 2010;30(8):910–8.PubMed Lev R, Granovsky Y, Yarnitsky D. Orbitofrontal disinhibition of pain in migraine with aura: an interictal EEG-mapping study. Cephalalgia. 2010;30(8):910–8.PubMed
43.
Zurück zum Zitat Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114(1–2):295–302.PubMedCrossRef Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain. 2005;114(1–2):295–302.PubMedCrossRef
44.
Zurück zum Zitat Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000;88(1):69–78.PubMedCrossRef Kosek E, Ordeberg G. Lack of pressure pain modulation by heterotopic noxious conditioning stimulation in patients with painful osteoarthritis before, but not following, surgical pain relief. Pain. 2000;88(1):69–78.PubMedCrossRef
45.
Zurück zum Zitat Murray M. Narrative psychology. In: Smith JA, editor. Qualitative psychology: A practical guide to research methods. London: Sage; 2008. p. 111–32. Murray M. Narrative psychology. In: Smith JA, editor. Qualitative psychology: A practical guide to research methods. London: Sage; 2008. p. 111–32.
46.
Zurück zum Zitat Elliott J. Using narrative in social research: Qualitative and quantitative approaches. London: Sage; 2005. Elliott J. Using narrative in social research: Qualitative and quantitative approaches. London: Sage; 2005.
47.••
Zurück zum Zitat McMahon L, Murray C, Simpson J. The potential benefits of applying a narrative analytic approach for understanding the experience of fibromyalgia: a review. Disabil Rehabil. 2012;34(13):1121–30. Recent and up-to-date coverage of the narrative approach.PubMedCrossRef McMahon L, Murray C, Simpson J. The potential benefits of applying a narrative analytic approach for understanding the experience of fibromyalgia: a review. Disabil Rehabil. 2012;34(13):1121–30. Recent and up-to-date coverage of the narrative approach.PubMedCrossRef
Metadaten
Titel
Personalized Treatment of Pain
verfasst von
Jacob N. Ablin
Dan Buskila
Publikationsdatum
01.01.2013
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 1/2013
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-012-0298-7

Weitere Artikel der Ausgabe 1/2013

Current Rheumatology Reports 1/2013 Zur Ausgabe

SCLERODERMA (J VARGA, SECTION EDITOR)

Morphogen Pathways in Systemic Sclerosis

CRYSTAL ARTHRITIS (MH PILLINGER, SECTION EDITOR)

Dual-Energy Computed Tomography for Gout Diagnosis and Management

CHRONIC PAIN (LJ CROFFORD, SECTION EDITOR)

Effect and Treatment of Chronic Pain in Inflammatory Arthritis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.